Zobrazeno 1 - 10
of 32
pro vyhledávání: '"David E. Ehmann"'
Autor:
Nancy Chen, David E. Ehmann, Robert Crooker, Katayoun Derakhchan, Xiaodong Fang, Brian Felice, Elizabeth J. Galbreath, Charles Glaus, Hongbo Gu, Yan Huang, Christine Li, Xing Li, Nan Liu, Kathleen Palmieri, Damir Simic, Joseph Sypek, Susan Thompson, Christopher T. Winkelmann, Vivian W. Choi
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 29, Iss , Pp 286-302 (2023)
Mucopolysaccharidosis II (MPS II) is a rare lysosomal storage disease characterized by deficient activity of iduronate-2-sulfatase (I2S), leading to pathological accumulation of glycosaminoglycans (GAGs) in tissues. We used iduronate-2-sulfatase knoc
Externí odkaz:
https://doaj.org/article/b33a6cf79e06450e92ea9144dc1312b7
Autor:
Andrea Iskenderian, Nan Liu, Qingwei Deng, Yan Huang, Chuan Shen, Kathleen Palmieri, Robert Crooker, Dianna Lundberg, Niksa Kastrapeli, Brian Pescatore, Alla Romashko, John Dumas, Robert Comeau, Angela Norton, Jing Pan, Haojing Rong, Katayoun Derakhchan, David E. Ehmann
Publikováno v:
Skeletal Muscle, Vol 8, Iss 1, Pp 1-16 (2018)
Abstract Background Myostatin antagonists are being developed as therapies for Duchenne muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered follistatin has the potential to combine the hypertrophy of myostatin a
Externí odkaz:
https://doaj.org/article/67bfaa2651914f7787073ccc6974c8c1
Autor:
Meera E. Modi, Katayoun Derakhchan, Christopher T. Winkelmann, Elizabeth J. Galbreath, David E. Ehmann
Publikováno v:
Molecular Genetics and Metabolism. 138:107227
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca8ae069c78f256b45f3cc5dc9d8dac1
https://doi.org/10.1016/j.ymgme.2022.107227
https://doi.org/10.1016/j.ymgme.2022.107227
Autor:
Kathleen Palmieri, Bohong Zhang, Muthuraman Meiyappan, Sheng Gu, Matthew Traylor, Brian Pescatore, Robert Crooker, Angela W. Norton, David E. Ehmann, Clark Pan, Dianna Lundberg, George Baviello, Chuan Shen, Qingwei Deng, Bettina Strack-Logue, Alla Romashko, Tao He, Andrea Iskenderian, Haojing Rong, John Gill
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 366:291-302
Follistatin (FS) is an important regulatory protein, a natural antagonist for transforming growth factor-β family members activin and myostatin. The diverse biologic roles of the activin and myostatin signaling pathways make FS a promising therapeut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b31d0c29b0ec54cf1d6e1bd8246deac9
https://doi.org/10.1124/jpet.118.248195
https://doi.org/10.1124/jpet.118.248195
Autor:
Robert E. McLaughlin, Elise Gorseth, Michael T. Rooney, Ann E. Eakin, Aryun Kim, Asha S. Nayar, Andy S. Tsai, Kerry E. Murphy-Benenato, Alita A. Miller, Jared L. Crandon, David P. Nicolau, Christina M. Blinn, April Chen, David E. Ehmann, Amy Kutschke, Brian Dangel, Sara A. Patey
Publikováno v:
Antimicrobial Agents and Chemotherapy. 59:7743-7752
The objective of this study was to investigate the risk of attenuated efficacy due to adaptive resistance for the siderophore-conjugated monocarbam SMC-3176 in Pseudomonas aeruginosa by using a pharmacokinetic/pharmacodynamic (PK/PD) approach. MICs w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34771f5a04a33c3d3142e2a0d2b73c23
https://doi.org/10.1128/aac.00831-15
https://doi.org/10.1128/aac.00831-15
Autor:
Jing Pan, Alla Romashko, David E. Ehmann, Katayoun Derakhchan, Angela W. Norton, Andrea Iskenderian, Qingwei Deng, Robert Comeau, Robert Crooker, Nan Liu, John Dumas, Chuan Shen, Niksa Kastrapeli, Dianna Lundberg, Brian Pescatore, Kathleen Palmieri, Haojing Rong, Yan Huang
Publikováno v:
Skeletal Muscle
Skeletal Muscle, Vol 8, Iss 1, Pp 1-16 (2018)
Skeletal Muscle, Vol 8, Iss 1, Pp 1-16 (2018)
Background Myostatin antagonists are being developed as therapies for Duchenne muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered follistatin has the potential to combine the hypertrophy of myostatin antagonism
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae2104cea901b16f8803bff66aa10bb0
https://pubmed.ncbi.nlm.nih.gov/30368252
https://pubmed.ncbi.nlm.nih.gov/30368252
Autor:
Robert A. Giacobbe, Adam B. Shapiro, Jason Thresher, Alita A. Miller, Boudewijn Dejonge, Michael D. Huband, William F. Penwell, David E. Ehmann, Rong-Fang Gu, Robert E. McLaughlin, Ning Gao
Publikováno v:
Antimicrobial Agents and Chemotherapy. 59:1680-1689
Sulbactam is a class A β-lactamase inhibitor with intrinsic whole-cell activity against certain bacterial species, including Acinetobacter baumannii . The clinical use of sulbactam for A. baumannii infections is of interest due to increasing multidr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e5dcd27449195d8495fe9e1e9aad358
https://doi.org/10.1128/aac.04808-14
https://doi.org/10.1128/aac.04808-14
Autor:
David E. Ehmann, Jason Thresher, Asha S. Nayar, Ning Gao, Folkert Reck, Adam B. Shapiro, Thomas J. Dougherty
Publikováno v:
Antimicrobial Agents and Chemotherapy. 59:331-337
In a previous report (T. J. Dougherty, A. Nayar, J. V. Newman, S. Hopkins, G. G. Stone, M. Johnstone, A. B. Shapiro, M. Cronin, F. Reck, and D. E. Ehmann, Antimicrob Agents Chemother 58:2657–2664, 2014), a novel bacterial type II topoisomerase inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce2632fda9d5d600daf271f08bf6541e
https://doi.org/10.1128/aac.04077-14
https://doi.org/10.1128/aac.04077-14
Autor:
Jean Denis Docquier, Filomena De Luca, David E. Ehmann, Sushmita D. Lahiri, Manuela Benvenuti, Stefano Mangani, Thomas F. Durand-Reville, Haris Jahic, Richard A. Alm, Gian Maria Rossolini
Publikováno v:
ACS Chemical Biology. 10:591-600
The Class D (or OXA-type) β-lactamases have expanded to be the most diverse group of serine β-lactamases with a highly heterogeneous β-lactam hydrolysis profile and are typically resistant to marketed β-lactamase inhibitors. Class D enzymes are i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db989968cb8f6a63e50438eb8cd0148d
https://doi.org/10.1021/cb500703p
https://doi.org/10.1021/cb500703p
Autor:
Sushmita D. Lahiri, David E. Ehmann
Publikováno v:
Current Opinion in Pharmacology. 18:76-83
Among the targets for the development of new antibacterial agents, bacterial topoisomerases remain a vibrant area of discovery. A structurally diverse set of inhibitors that bind to the adenosine 5'-triphosphate (ATP) site of type II topoisomerases h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2731081bf602a3f7b0f356e7a061814